Health Canada Approves Abbott’s Dissolvable Stent for Below-the-Knee Artery Disease
Abbott has received Health Canada authorisation for its Esprit BTK Everolimus Eluting Resorbable Scaffold System, a dissolvable stent developed for patients with chronic limb-threatening ischemia (CLTI) affecting below-the-knee arteries.
Traditionally, balloon angioplasty has been the standard treatment, where a balloon presses arterial blockages against the vessel wall to restore blood flow. However, the approach often leads to recurrent narrowing and repeat interventions. Abbott’s new scaffold, made from a material similar to dissolving sutures, offers a minimally invasive alternative. Inserted via a catheter-based leg incision, it props the artery open while releasing the drug everolimus to aid healing.
The device provides support for up to three years before dissolving, allowing the vessel to function on its own. Results from the LIFE-BTK trial, presented at the 2024 VIVA Conference, showed a 48% reduction in repeat procedures compared to balloon angioplasty, demonstrating improved long-term outcomes.
30-09-2025
📰 Recent News
- Health Canada Approves Abbott’s Dissolvable Stent for Below-the-Knee Artery Disease
- FDA Clears Active Life’s OsteoProbe for Bone Material Strength Measurement
- FDA Clears Zenflow’s Spring Scope to Improve Urology Procedures
- Hologic Gains FDA Clearance for First GI Pathogen Detection Assays
- Olympus Recalls Lung Biopsy Needles After Reports of Injuries and Death
- Johnson & Johnson Recalls Impella Controllers Following Purge Pressure Faults
- Medtronic Expands London AI and Robotics Hub as Virtuoso Robot Gains FDA Breakthrough Designation
- Heartflow Gains FDA Clearance for Updated Plaque Analysis Algorithm
- FDA Grants De Novo Clearance to Biolinq’s Needle-Free CGM for Type 2 Diabetes
- BD Broadens Recall of Alaris Infusion Sets Over Safety Risks